前沿生物(688221.SH)：预计2025年度净亏损约2.55亿元到亏损2.9亿元

Core Viewpoint - Frontier Biotech (688221.SH) expects to achieve a revenue of approximately 140 million to 145 million yuan in 2025, representing a year-on-year increase of 8.13% to 11.99%, primarily driven by sales of its innovative HIV drug Aikening® (generic name: Abacavir), the agency product Viread® (Tenofovir Disoproxil Fumarate), and the newly approved far-infrared therapy patch (Xiaoyan Yipian®) [1] Revenue Forecast - The company anticipates that its revenue for 2025 will be between 140 million and 145 million yuan, reflecting a growth of 8.13% to 11.99% compared to the previous year [1] - The revenue growth is mainly attributed to the sales of Aikening®, Viread®, and the newly approved far-infrared therapy patch [1] Profit Forecast - The company projects a net loss attributable to shareholders of approximately 255 million to 290 million yuan for 2025, which is an increase in loss of about 53.62 million to 88.62 million yuan [1] - This increase in loss is primarily due to the absence of investment income from the disposal of subsidiary equity, which generated 71.84 million yuan in 2024 [1] - The expected net loss attributable to shareholders after excluding non-recurring gains and losses is estimated to be between 288 million and 323 million yuan, reflecting a reduction in loss of approximately 4.31 million to 39.31 million yuan, mainly due to revenue growth and reduced operating expenses [1]